A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 di...
A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy
About this item
Full title
Author / Creator
Publisher
Tokyo: Springer Japan
Journal title
Language
English
Formats
Publication information
Publisher
Tokyo: Springer Japan
Subjects
More information
Scope and Contents
Contents
Objective
To identify the attenuating factor of glycated hemoglobin (HbA1c)-lowering effects of liraglutide in type 2 diabetes (T2D) patients over the long term.
Methods
Forty-six T2D patients received liraglutide-glimepiride combination therapy. Clinical characteristics were compared between the following two subgroups: the relapse group...
Alternative Titles
Full title
A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6224977
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6224977
Other Identifiers
ISSN
2190-1678
E-ISSN
2190-1686
DOI
10.1007/s13340-016-0269-8
